Ocean Biomedical Inc is a biotechnology company focused on discovering and developing innovative therapies for various diseases, particularly in the fields of infectious diseases and cancer
The company employs cutting-edge research and technology to identify unique biological targets and create novel treatment options. By collaborating with leading academic institutions and leveraging advancements in science, Ocean Biomedical aims to bring new medical solutions to market, enhancing patient care and addressing unmet medical needs. Their commitment to driving scientific progress positions them as a key player in the biopharmaceutical landscape.
Shares of HighPeak Energy, Inc. (NASDAQHPK) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter revenue results.
Shares of SOPHiA GENETICS SA (NASDAQSOPH) fell sharply during Tuesday’s session after the company reported worse than expected fourth-quarter earnings and issued 2024 guidance.
PALM BEACH, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is one of the leading causes of cancer death globally. The increasing incidence of this cancer across the U.S. and other parts of the world is one of the factors driving the need for the drugs used in the treatment. Moreover, the prevalence is significantly higher in the geriatric population compared to other types of cancers. Thus, an increase in the geriatric population is one factor driving the pancreatic cancer treatment market growth. The incidence is significantly higher in the geriatric population above 65 years of age compared to other types of cancers. A report from Fortune Business Insights said that: “the pancreatic cancer treatment market size is projected to grow to USD 6.85 billion by 2029, exhibiting a CAGR of 15.7% during 2022-2029. North America dominated the global market with a share of 46.97% in 2022. The increase in the number of patients suffering from the condition has increased the demand for the drugs used in treatment. These are some factors driving the growth during the forecast period. Companies engaged in manufacturing cancer drugs have increased their focus on R&D activities to develop new drugs for pancreatic cancer treatment. Additionally, the companies operating in the market have received approval from several regulatory bodies, such as the U.S. Food and Drug Administration (FDA), the Medicines and Healthcare Products Regulatory Agency (MHRA) (U.K.), among others, thereby propelling the growth of the market. Moreover, new testing technologies are being adopted by hospitals and diagnostic centers to diagnose cancer. The increase in the diagnosis rates is driving the demand for drugs, thereby providing opportunities for the players.” Active biotech and pharma companies in the markets this week include Oncolytics Biotech® Inc. (NASDAQONCY) (TSX: ONC), Ocean Biomedical, Inc. NASDAQ: OCEANASDAQOCEA)(NASDAQ: LVTXNASDAQLVTX, Merck & Co., Inc. (NYSE: MRKNYSE), AbbVie Inc. (NYSE: ABBVABBV).
